# Safety and Pharmacokinetic Study of Intranasal 2-DG in Healthy Volunteers

> **NCT05314933** · PHASE1 · COMPLETED · sponsor: **G.ST Antivirals GmbH** · enrollment: 45 (actual)

## Conditions studied

- Acute Nasopharyngitis

## Interventions

- **DRUG:** 2-Deoxyglucose
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05314933
- **Lead sponsor:** G.ST Antivirals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-03
- **Primary completion:** 2023-08-01
- **Final completion:** 2023-09-27
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2023-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05314933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05314933, "Safety and Pharmacokinetic Study of Intranasal 2-DG in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05314933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*